KRT18 and breast carcinoma: In another study in patients with recurrent breast cancer (n=32) receiving chemotherapy with cyclophosphamide, epirubicin and 5-flourouracil or docetaxel (Biven et al, 2003), an index was calculated for each patient based on the difference between the maximum CK18–Asp396 level observed during treatment and the pretreatment level.